

FILE 'REGISTRY' ENTERED AT 10:01:55 ON 18 JUL 2007

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 34 S L1 SSS FULL
L4 STRUCTURE UPLOADED

FILE 'CAPLUS' ENTERED AT 10:05:32 ON 18 JUL 2007

L5 13 S L3/THU
L6 8 S L5 AND (PY<2001 OR AY<2001 OR PRY<2001)

=> file registry
COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 10:01:55 ON 18 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JUL 2007 HIGHEST RN 942577-08-4
DICTIONARY FILE UPDATES: 17 JUL 2007 HIGHEST RN 942577-08-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10635444claim1.str



chain nodes :

ring nodes :

Ring nodes:

chain bonds

1-51 2-41 3-50 4-53 8-43 8-44 9-45 9-46 10-47 10-48 11-12 12-13 13-14
14-15 14-26 15-16 16-17 17-18 18-19 18-25 19-20 20-21 21-22 22-23 22-24
27-28 27-35

28-29	28-36	29-30	29-31	31-32	32-37	32-38	32-39	41-162	54-55	55-56	56-57
56-58	59-60										
59-63	59-64	60-61	60-62	62-72	65-66	65-69	65-70	66-67	66-68	68-71	73-74
73-77	73-78										
74-75	74-76	76-79	76-80	79-81	80-84	81-82	81-83	84-85	84-86	93-94	94-95
95-96	96-97	96-98									
98-99	99-100	100-101	101-102	101-103	105-106	106-107	108-109	109-110			
110-111	112-113										
113-114	114-115	115-116	120-121	121-122	122-123	123-124	124-125	125-126			
126-127	127-128										
128-129	129-130	130-131	131-132	132-133	133-134	134-135	135-136	137-138			
138-139	139-140										
140-141	141-142	142-143	143-144	144-145	145-146	146-147	147-148	148-149			
150-151	151-152										
152-153	153-154	154-155	155-156								
ring bonds :											
1-2	1-6	2-3	3-4	4-5	5-6	5-7	6-10	7-8	8-9	9-10	
exact/norm bonds :											
1-51	2-41	3-50	4-53	5-7	6-10	7-8	8-9	8-43	8-44	9-10	9-45
10-48	11-12	12-13	13-14	14-15	14-26	15-16	16-17	17-18	18-19	18-25	19-20
20-21	21-22										
22-23	22-24	27-28	27-35	28-29	28-36	29-30	29-31	31-32	32-37	32-38	32-39
41-162	54-55										
55-56	59-60	59-63	59-64	60-61	60-62	62-72	65-66	65-69	65-70	66-67	66-68
68-71	73-74	73-77									
73-78	74-75	74-76	76-79	76-80	79-81	80-84	93-94	94-95	95-96	96-97	96-98
98-99	99-100										
100-101	101-102	101-103	105-106	106-107	108-109	109-110	110-111	112-113			
113-114	114-115										
115-116	120-121	121-122	122-123	123-124	124-125	125-126	126-127	127-128			
128-129	129-130										
130-131	131-132	132-133	133-134	134-135	135-136	137-138	138-139	139-140			
140-141	141-142										
142-143	143-144	144-145	145-146	146-147	147-148	148-149	150-151	151-152			
152-153	153-154										
154-155	155-156										
normalized bonds :											
1-2	1-6	2-3	3-4	4-5	5-6	56-57	56-58	81-82	81-83	84-85	84-86

G1:O,S,N

G2:O,N

G3:H,CH₃

G4:CH₃,COOH,[*1],[*2],[*3],[*4],[*5],[*6]

G5:[*7],[*8],[*9],[*10],[*11],[*12],[*13]

Match level :

1:Atom	2:Atom	3:Atom	4:Atom	5:Atom	6:Atom	7:Atom	8:Atom	9:Atom	10:Atom
11:CLASS	12:CLASS	13:CLASS	14:CLASS	15:CLASS	16:CLASS	17:CLASS	18:CLASS		
19:CLASS	20:CLASS								
21:CLASS	22:CLASS	23:CLASS	24:CLASS	25:CLASS	26:CLASS	27:CLASS	28:CLASS		
29:CLASS	30:CLASS								
31:CLASS	32:CLASS	35:CLASS	36:CLASS	37:CLASS	38:CLASS	39:CLASS	41:CLASS		
43:CLASS	44:CLASS								
45:CLASS	46:CLASS	47:CLASS	48:CLASS	50:CLASS	51:CLASS	53:CLASS	54:CLASS		
55:CLASS	56:CLASS								
57:CLASS	58:CLASS	59:CLASS	60:CLASS	61:CLASS	62:CLASS	63:CLASS	64:CLASS		
65:CLASS	66:CLASS								
67:CLASS	68:CLASS	69:CLASS	70:CLASS	71:CLASS	72:CLASS	73:CLASS	74:CLASS		
75:CLASS	76:CLASS								

77:CLASS 78:CLASS 79:CLASS 80:CLASS 81:CLASS 82:CLASS 83:CLASS 84:CLASS
85:CLASS 86:CLASS
93:CLASS 94:CLASS 95:CLASS 96:CLASS 97:CLASS 98:CLASS 99:CLASS 100:CLASS
101:CLASS
102:CLASS 103:CLASS 105:CLASS 106:CLASS 107:CLASS 108:CLASS 109:CLASS
110:CLASS 111:CLASS
112:CLASS 113:CLASS 114:CLASS 115:CLASS 116:CLASS 120:CLASS 121:CLASS
122:CLASS 123:CLASS
124:CLASS 125:CLASS 126:CLASS 127:CLASS 128:CLASS 129:CLASS 130:CLASS
131:CLASS 132:CLASS
133:CLASS 134:CLASS 135:CLASS 136:CLASS 137:CLASS 138:CLASS 139:CLASS
140:CLASS 141:CLASS
142:CLASS 143:CLASS 144:CLASS 145:CLASS 146:CLASS 147:CLASS 148:CLASS
149:CLASS 150:CLASS
151:CLASS 152:CLASS 153:CLASS 154:CLASS 155:CLASS 156:CLASS 162:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:03:09 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 8750 TO ITERATE

22.9% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 169393 TO 180607

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 10:03:29 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 174859 TO ITERATE


100.0% PROCESSED 174859 ITERATIONS 34 ANSWERS
SEARCH TIME: 00.00.01

L3 34 SEA SSS FUL L1

=> d l3 scan

L3 34 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[(3,4-dihydro-
2,2,7,8-tetramethyl-2H-1-benzopyran-6-yl)oxy]acetyl]amino]phenylacetyl]ami-
no]-3,3-dimethyl-7-oxo-, [2S-[2 α ,5 α ,6 β (S*)]]- (9CI)
MF C31 H37 N3 O7 S

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5


L3 34 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[(3,4-dihydro-2,2,7,8-tetramethyl-2H-1-benzopyran-6-yl)thio]acetyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2 α ,5 α ,6 β (S*)]]- (9CI)
 MF C31 H37 N3 O6 S2

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 34 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Propanoic acid, 3-[(3,4-dihydro-2,2,5,7,8-pentamethyl-2H-1-benzopyran-6-yl)oxy]- (9CI)
 MF C17 H24 O4



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Poly(oxy-1,2-ethanediyl), α -[3,4-dihydro-2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]- ω -hydroxy- (9CI)
 MF $(C_2 H_4 O)_n C_{28} H_{48} O_2$
 CI PMS

PAGE 1-A




PAGE 1-B

$—(CH_2)_3—CHMe_2$

L3 34 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Ethanol, 2-[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy- (9CI)
 MF C₃₁ H₅₄ O₃


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 34 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Acetamide, 2-[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy- (9CI)
 MF C₃₁ H₅₃ N O₃

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\Stnexp\Queries\10635444claim1b.str



chain nodes :

11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
32 35 36 37 38 39 41 43 44 45 46 47 48 50 51 53 54 55 56 57 58
59 60 61
62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82
83 84 85 86
93 94 95 96 97 98 99 100 101 102 103 105 106 107 108 109 110 111
112 113 114
115 116 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134
135 136 137
138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154
155 156 162
163

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

1-51 2-41 3-50 4-53 8-43 8-44 9-45 9-46 10-47 10-48 11-12 12-13 13-14
14-15 14-26 15-16 16-17 17-18 18-19 18-25 19-20 20-21 21-22 22-23 22-24
27-28 27-35
28-29 28-36 29-30 29-31 31-32 32-37 32-38 32-39 41-162 54-55 55-56 56-57
56-58 59-60
59-63 59-64 60-61 60-62 62-72 62-163 65-66 65-69 65-70 66-67 66-68 68-71
73-74 73-77
73-78 74-75 74-76 76-79 76-80 79-81 80-84 81-82 81-83 84-85 84-86 93-94
94-95 95-96
96-97 96-98 98-99 99-100 100-101 101-102 101-103 105-106 106-107 108-109
109-110 110-111
112-113 113-114 114-115 115-116 120-121 121-122 122-123 123-124 124-125
125-126 126-127
127-128 128-129 129-130 130-131 131-132 132-133 133-134 134-135 135-136
137-138 138-139
139-140 140-141 141-142 142-143 143-144 144-145 145-146 146-147 147-148
148-149 150-151
151-152 152-153 153-154 154-155 155-156

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10

exact/norm bonds :

1-51 2-41 3-50 4-53 5-7 6-10 7-8 8-9 8-43 8-44 9-10 9-45 9-46 10-47
10-48 11-12 12-13 13-14 14-15 14-26 15-16 16-17 17-18 18-19 18-25 19-20
20-21 21-22
22-23 22-24 27-28 27-35 28-29 28-36 29-30 29-31 31-32 32-37 32-38 32-39
41-162 54-55
55-56 59-60 59-63 59-64 60-61 60-62 62-72 62-163 65-66 65-69 65-70 66-67
66-68 68-71
73-74 73-77 73-78 74-75 74-76 76-79 76-80 79-81 80-84 93-94 94-95 95-96
96-97 96-98 98-99
99-100 100-101 101-102 101-103 105-106 106-107 108-109 109-110 110-111
112-113 113-114
114-115 115-116 120-121 121-122 122-123 123-124 124-125 125-126 126-127
127-128 128-129
129-130 130-131 131-132 132-133 133-134 134-135 135-136 137-138 138-139
139-140 140-141
141-142 142-143 143-144 144-145 145-146 146-147 147-148 148-149 150-151
151-152 152-153
153-154 154-155 155-156

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 56-57 56-58 81-82 81-83 84-85 84-86

G1:O,S,N

G2:O,N

G3:H,CH3

G4 : CH₃, COOH, [*1], [*2], [*3], [*4], [*5], [*6]

G5 : [*7], [*8], [*9], [*10], [*11], [*12], [*13]

Match level :

1:Atom	2:Atom	3:Atom	4:Atom	5:Atom	6:Atom	7:Atom	8:Atom	9:Atom	10:Atom
11:CLASS	12:CLASS	13:CLASS	14:CLASS	15:CLASS	16:CLASS	17:CLASS	18:CLASS		
19:CLASS	20:CLASS								
21:CLASS	22:CLASS	23:CLASS	24:CLASS	25:CLASS	26:CLASS	27:CLASS	28:CLASS		
29:CLASS	30:CLASS								
31:CLASS	32:CLASS	35:CLASS	36:CLASS	37:CLASS	38:CLASS	39:CLASS	41:CLASS		
43:CLASS	44:CLASS								
45:CLASS	46:CLASS	47:CLASS	48:CLASS	50:CLASS	51:CLASS	53:CLASS	54:CLASS		
55:CLASS	56:CLASS								
57:CLASS	58:CLASS	59:CLASS	60:CLASS	61:CLASS	62:CLASS	63:CLASS	64:CLASS		
65:CLASS	66:CLASS								
67:CLASS	68:CLASS	69:CLASS	70:CLASS	71:CLASS	72:CLASS	73:CLASS	74:CLASS		
75:CLASS	76:CLASS								
77:CLASS	78:CLASS	79:CLASS	80:CLASS	81:CLASS	82:CLASS	83:CLASS	84:CLASS		
85:CLASS	86:CLASS								
93:CLASS	94:CLASS	95:CLASS	96:CLASS	97:CLASS	98:CLASS	99:CLASS	100:CLASS		
101:CLASS									
102:CLASS	103:CLASS	105:CLASS	106:CLASS	107:CLASS	108:CLASS	109:CLASS			
110:CLASS	111:CLASS								
112:CLASS	113:CLASS	114:CLASS	115:CLASS	116:CLASS	120:CLASS	121:CLASS			
122:CLASS	123:CLASS								
124:CLASS	125:CLASS	126:CLASS	127:CLASS	128:CLASS	129:CLASS	130:CLASS			
131:CLASS	132:CLASS								
133:CLASS	134:CLASS	135:CLASS	136:CLASS	137:CLASS	138:CLASS	139:CLASS			
140:CLASS	141:CLASS								
142:CLASS	143:CLASS	144:CLASS	145:CLASS	146:CLASS	147:CLASS	148:CLASS			
149:CLASS	150:CLASS								
151:CLASS	152:CLASS	153:CLASS	154:CLASS	155:CLASS	156:CLASS	162:CLASS			
163:CLASS									

L4 STRUCTURE UPLOADED

=> file caplus			
COST IN U.S. DOLLARS		SINCE FILE	TOTAL
FULL ESTIMATED COST		ENTRY	SESSION
		174.35	174.56

FILE 'CAPLUS' ENTERED AT 10:05:32 ON 18 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jul 2007 VOL 147 ISS 4
FILE LAST UPDATED: 17 Jul 2007 (20070717/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13/thu

35 L3

913397 THU/RL

L5 13 L3/THU

(L3 (L) THU/RL)

=> s 15 and (PY<2001 or AY<2001 or PRY<2001)

20938905 PY<2001

3907654 AY<2001

3386616 PRY<2001


L6 8 L5 AND (PY<2001 OR AY<2001 OR PRY<2001)

=> d 16 1-8 ti abs bib hitstr

L6 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of tocopherols, tocotrienols, other chroman and side chain derivatives for therapeutic use in the prevention and treatment of cancer

GI



AB Chroman derivs., such as I [X = O, S, NR6; Y = O, NR6; R1 = carboxyalkyl, carboxyalkenyl, etc.; R2, R3, R4 = H, Me, alkyl, etc.; R5 = alkyl, alkenyl, etc.; R6 = H, alkyl], were prepared for use in antitumor pharmaceutical comps. for inducing apoptosis in a cell, particularly a cancer cell. Thus, α -tocopherol derivative II was prepared in 88% yield by a reaction of BrCH₂CO₂Me with (R,R,R)- α -tocopherol using NaOH in DMF. The prepared chromans were assayed for growth inhibitory and apoptotic activity against a variety of human cancer cell lines.

AN 2004:618733 CAPLUS <<LOGINID::20070718>>

DN 141:174332

TI Preparation of tocopherols, tocotrienols, other chroman and side chain derivatives for therapeutic use in the prevention and treatment of cancer

IN Sanders, Bob G.; Kline, Kimberly; Hurley, Laurence; Gardner, Robb;
Menchaca, Marla; Yu, Weiping; Ramanan, Puthucode N.; Liu, Shenquan;
Israel, Karen

PA Research Development Foundation, USA

SO U.S., 48 pp., Cont.-in-part of U.S. Ser. No. 404,001.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6770672	B1	20040803	US 2000-502592	20000211 <--
	US 6417223	B1	20020709	US 1999-404001	19990923 <--
	CA 2399802	A1	20010816	CA 2001-2399802	20010209 <--
	WO 2001058889	A1	20010816	WO 2001-US4168	20010209 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1254130	A1	20021106	EP 2001-909008	20010209 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004504268	T	20040212	JP 2001-558439	20010209 <--
	NZ 520798	A	20040528	NZ 2001-520798	20010209 <--
	CN 1529701	A	20040915	CN 2001-807536	20010209 <--
	RU 2263672	C2	20051110	RU 2002-124135	20010209 <--
	US 2002107207	A1	20020808	US 2001-8066	20011105 <--
	US 6703384	B2	20040309		
	US 2004235938	A1	20041125	US 2003-644418	20030820 <--
	US 2004097431	A1	20040520	US 2003-695275	20031028 <--
PRAI	US 1998-101543P	P	19980923	<--	
	US 1999-404001	A2	19990923	<--	
	US 1998-101542P	P	19980923	<--	
	US 2000-502592	A	20000211	<--	
	WO 2001-US4168	W	20010209		
	US 2001-8066	A3	20011105		

OS MARPAT 141:174332


IT 200701-54-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of tocopherols, tocotrienols, other chroman and side chain derivs. for therapeutic use in prevention and treatment of cancer)

RN 200701-54-8 CAPLUS

CN Ethanol, 2-[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 261929-53-7P 261929-60-6P 261929-61-7P
261929-62-8P 261929-67-3P 261929-70-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tocopherols, tocotrienols, other chroman and side chain derivs. for therapeutic use in prevention and treatment of cancer)

RN 261929-53-7 CAPLUS

CN Propanoic acid, 3-[[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 261929-60-6 CAPLUS

CN Acetamide, 2-[[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 261929-61-7 CAPLUS

CN Acetic acid, [[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 261929-62-8 CAPLUS


CN Glycine, N-(carboxymethyl)-N-[[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 261929-67-3 CAPLUS

CN 1-Propanamine, 3-[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B



RN 261929-70-8 CAPLUS


CN Ethanol, 2-[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-, hydrogen sulfate, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 261929-69-5
CMF C31 H54 O6 S

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


— CHMe₂

CM 2

CRN 121-44-8
CMF C6 H15 N




IT 354526-64-0P 354526-65-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)
(preparation of tocopherols, tocotrienols, other chroman and side chain
derivs. for therapeutic use in prevention and treatment of cancer)
RN 354526-64-0 CAPLUS
CN Acetic acid, [[1,2,3,4-tetrahydro-2,5,7,8-tetramethyl-2-(4,8,12-
trimethyltridecyl)-6-quinolinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)





RN 354526-65-1 CAPLUS

CN Acetic acid, [[1,2,3,4-tetrahydro-1,2,5,7,8-pentamethyl-2-(4,8,12-trimethyltridecyl)-6-quinolinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
TI Industrial preparation of water-soluble and vitamin-active polyethylene glycol ethers of tocopherol
GI



AB The invention relates to novel polyethylene glycol ethers of tocopherol of formula I [wherein: R¹, R², R³ = H, Me (corresponding to tocopherols α, β, γ, δ, ε, η, δ); n = 101-150] useful in chemical, medicine, cosmetol., and food industry due to their vitamin activity (vitamin E) and water solubility Compds. I are prepared via industrial scale reaction of tocopherol esters with ethylene oxide in the presence of alkali at 120-150 °C, with the ethylene oxide being supplied at such velocity as to maintain the temperature of the reaction mixture within the defined limits. The process is carried out in an autoclave at a pressure of 1-3 atm and an ethylene oxide-to-tocopherol molar ratio between 25:1 and 150:1. The proposed method is a cost-effective preparation of water-soluble and vitamin-active tocopherol derivs. containing long polyethylene

glycol chains. For instance, compound II ($n = 110$) was prepared via reaction of α -tocopherol acetate with ethylene oxide in the presence of KOH with a yield of 84%. The compds. I retain the vitamin activity of the corresponding tocopherol acetates (no data).

AN 2003:482531 CAPLUS <<LOGINID::20070718>>

DN 140:235911

TI Industrial preparation of water-soluble and vitamin-active polyethylene glycol ethers of tocopherol

IN Kalinichenko, A. N.; Sotnikov, P. S.; Morozova, Z. V.; Danilenko, L. V.

PA OOO "MDT", Russia

SO Russ., No pp. given

CODEN: RUXXE7

DT Patent

LA Russian

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	RU 2201926	C2	20030410	RU 2000-115916	20000622 <--
PRAI	RU 2000-115916				
IT	74707-11-2P 146598-22-3P 146598-23-4P 146683-37-6P		20000622 <--		

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(industrial preparation of water-soluble and vitamin-active polyethylene glycol

ethers of tocopherols prepared via reaction of tocopherol esters with ethylene oxide)

RN 74707-11-2 CAPLUS

CN Poly(oxy-1,2-ethanediyl), α -[3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]- ω -hydroxy-, (2R)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

$-\text{CH}_2\text{CH}_2\text{O}-$

RN 146598-22-3 CAPLUS

CN Poly(oxy-1,2-ethanediyl), α -[3,4-dihydro-2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]- ω -hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

$$-\text{CH}_2\text{CH}_2\text{CH}_2\text{CHMe}_2$$

RN 146598-23-4 CAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[3,4-dihydro-2,5,8-trimethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]-ω-hydroxy- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B


$$-\text{CH}_2\text{CH}_2\text{CH}_2\text{CHMe}_2$$

RN 146683-37-6 CAPLUS
CN Poly(oxy-1,2-ethanediyl), α-[(2R)-3,4-dihydro-2,8-dimethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]-ω-hydroxy-(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B



L6 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of tocopherols, tocotrienols, other chromans and side chain
derivs. as potential antiproliferative and proapoptotic agents
GI



AB Derivs. of tocopherol, tocotrienol and other chromans of formula I (X and Y independently are oxygen, nitrogen or sulfur; when Y is nitrogen, nitrogen is substituted with R₆ and R₆ = H or Me; R₁ = alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxylic acid, carboxylate, carboxamide, ester, thioamide, thiolacid, thiol ester, saccharide, alkoxy-linked saccharide, amine, sulfonate, sulfate, phosphate, alc., ethers or nitrites; R₂, R₃ = hydrogen or R₄; R₄ = Me, benzyl carboxylic acid, benzyl carboxylate, benzyl carboxamide, benzyl ester, saccharide or amine; and R₅ = alkenyl) were prepared as antiproliferative and proapoptotic agents for the potential treatment of cell proliferative diseases. Thus, α -tocopherol was treated with Me bromoacetate and NaOH in N, N-dimethylformamide to give II. II showed effective growth inhibitory


properties (apoptotic inducing) in a wide variety of human cancer cell lines, including breast, prostate, cervical, and ovarian cancers with EC50 values ranging from 1-20 µg/mL.

AN 2002:595501 CAPLUS <<LOGINID::20070718>>
DN 137:140656
TI Preparation of tocopherols, tocotrienols, other chromans and side chain derivs. as potential antiproliferative and proapoptotic agents
IN Sanders, Bob G.; Kline, Kimberly; Yu, Weiping
PA Research Development Foundation, USA
SO U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U. S. Ser. No. 502,592.
CODEN: USXXCO
DT Patent
LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002107207	A1	20020808	US 2001-8066	20011105 <--
	US 6703384	B2	20040309		
	US 6417223	B1	20020709	US 1999-404001	19990923 <--
	CN 1706838	A	20051214	CN 2005-10003855	19990923 <--
	US 6770672	B1	20040803	US 2000-502592	20000211 <--
	US 2002156024	A1	20021024	US 2002-122019	20020412 <--
	US 6645998	B2	20031111		
	WO 2003039461	A2	20030515	WO 2002-US35147	20021101
	WO 2003039461	A3	20031113		
		W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW		
		RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	AU 2002353971	A1	20030519	AU 2002-353971	20021101
	US 2004097431	A1	20040520	US 2003-695275	20031028 <--
PRAI	US 1998-101542P	P	19980923	<--	
	US 1999-404001	A2	19990923	<--	
	US 2000-502592	A2	20000211	<--	
	US 1998-101543P	P	19980923	<--	
	CN 1999-812829	A3	19990923	<--	
	US 2001-8066	A	20011105		
	WO 2002-US35147	W	20021101		
OS	MARPAT 137:140656				
IT	200701-54-8P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(preparation of tocopherols, tocotrienols, other chromans and side chain derivs. as potential antiproliferative, proapoptotic agents for the treatment of cancer)				
RN	200701-54-8 CAPLUS				
CN	Ethanol, 2-[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy] - (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



IT 261929-53-7P 261929-60-6P 261929-61-7P
261929-62-8P 261929-67-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tocopherols, tocotrienols, other chromans and side chain derivs. as potential antiproliferative, proapoptotic agents for the treatment of cancer)

RN 261929-53-7 CAPLUS

CN Propanoic acid, 3-[[*(2R)*-3,4-dihydro-2,5,7,8-tetramethyl-2-[*(4R,8R)*-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 261929-60-6 CAPLUS

CN Acetamide, 2-[[*(2R)*-3,4-dihydro-2,5,7,8-tetramethyl-2-[*(4R,8R)*-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 261929-61-7 CAPLUS

CN Acetic acid, [[*(2R)*-3,4-dihydro-2,5,7,8-tetramethyl-2-[*(4R,8R)*-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 261929-62-8 CAPLUS

CN Glycine, N-(carboxymethyl)-N-[[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]acetyl] - (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

$-\text{CH}_2\text{CH}_2\text{CH}_2\text{CHMe}_2$

RN 261929-67-3 CAPLUS

CN 1-Propanamine, 3-[[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

— CHMe₂

L6 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Storage-stable compositions of glycerol monoalkyl ethers
 AB The present invention relates to compns. which comprise a combination (a) of 1 or more glycerol monoalkyl ethers, $\text{ROCH}_2\text{CHOHCH}_2\text{OH}$ (where R= a branched or unbranched C3-18 alkyl, in which the alkyl group can be substituted by 1 or more hydroxyl and/or C1-4 alkoxy and/or the alkyl chain can be interrupted by up to 4 oxygen atoms), and (b) an antioxidant or 2 or more antioxidants as stabilizers, the simultaneous presence of phosphocholines and phosphocholine derivs. being excluded.
 3-[(2-Ethylhexyl)oxy]-1,2-propanediol (Sensiva SC50) was mixed with a variety of substances, and the stability of the compns. during storage at room temperature in blue polyethylene bottles was tested. Following preparation of


the samples, the value for ppm of H_2O_2 and the pH were determined at regular intervals. BHT, BHA, vitamin E and dexpanthenol stabilize the glycerol monoalkyl ethers over a long period, and in particular the appearance of peroxides, determined by the Merckoquant peroxide test, is avoided and as a result the neck-in effect is no longer observed when the antioxidants are used.

AN 2001:903775 CAPLUS <<LOGINID::20070718>>
 DN 136:42534
 TI Storage-stable compositions of glycerol monoalkyl ethers
 IN Beilfuss, Wolfgang; Gradtke, Ralf
 PA Air Liquide Sante (International), Fr.; Schuelke & Mayr G.m.b.H.
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 2001093825	A1	20011213	WO 2001-IB865	20010517 <--
W: BR, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				

DE 10028638 A1 20011220 DE 2000-10028638 20000609 <--
 EP 1301168 A1 20030416 EP 2001-928160 20010517 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI, CY, TR
 JP 2003535116 T 20031125 JP 2002-501398 20010517 <--
 BR 2001011532 A 20040706 BR 2001-11532 20010517 <--
 EP 1806123 A2 20070711 EP 2007-105644 20010517 <--
 R: DE, ES, FR, GB, IT
 US 2003149097 A1 20030807 US 2002-297795 20021209 <--
 US 6956062 B2 20051018
 US 2005238681 A1 20051027 US 2005-159056 20050622 <--
 PRAI DE 2000-10028638 A 20000609 <--
 EP 2001-928160 A3 20010517
 WO 2001-IB865 W 20010517
 US 2002-297795 A1 20021209
 OS MARPAT 136:42534
 IT 74707-11-2
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (storage-stable compns. of glycerol monoalkyl ethers)
 RN 74707-11-2 CAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -[3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]- ω -hydroxy-, (2R)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— (CH₂)₃—CHMe₂

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Preparation of tocopherols, tocotrienols, other chroman and side chain
 derivatives that induce cell apoptosis for therapeutic use as
 antiproliferative agents
 GI



AB Tocopherol analogs, such as I [X = O, NH, S; Y = O, NH, S; R1 = alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxyl, carboxamide, thiocarboxyl, etc.; R2, R3, R4 = H, Me, benzyl, carboxyl, carboxamide, amine, saccharide; R5 = alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxyl, carboxamide], were prepared for pharmaceutical use as antiproliferative agents which induce cell apoptosis for treatment of cancers and diseases involving cell proliferation, such as autoimmune diseases, psoriasis, etc.. Thus, (R,R,R)- α -tocopherol derivative II was prepared in 88% yield by condensation of (R,R,R)- α -tocopherol and BrCH₂CO₂Me in DMF using NaOH followed by hydrolysis with 5 N HCl. The prepared tocopherol analogs were tested for their ability to induce apoptosis in a number of cancer cell lines, such as breast, cervical, colon, prostate, etc.

AN 2001:597976 CAPLUS <<LOGINID::20070718>>

DN 135:166941

TI Preparation of tocopherols, tocotrienols, other chroman and side chain derivatives that induce cell apoptosis for therapeutic use as antiproliferative agents

IN Sanders, Robert G.; Kline, Kimberly; Hurley, Laurence; Gardner, Robb; Menchaca, Marla; Yu, Weiping; Ramanan, Puthucode N.; Liu, Shenquan; Israel, Karen

PA Research Development Foundation, USA

SO PCT Int. Appl., 120 pp.

CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 4


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001058889	A1	20010816	WO 2001-US4168	20010209 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US	6770672	B1	20040803	US 2000-502592	20000211 <--
CA	2399802	A1	20010816	CA 2001-2399802	20010209 <--
EP	1254130	A1	20021106	EP 2001-909008	20010209 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP	2004504268	T	20040212	JP 2001-558439	20010209 <--
NZ	520798	A	20040528	NZ 2001-520798	20010209 <--

RU 2263672 C2 20051110 RU 2002-124135 20010209 <--
 PRAI US 2000-502592 A 20000211 <--
 US 1998-101543P P 19980923 <-- .
 US 1999-404001 A2 19990923 <--
 WO 2001-US4168 W 20010209
 OS MARPAT 135:166941
 IT 200701-54-8P 354526-64-0P 354526-65-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of tocopherols, tocotrienols, other chromans that induce cell apoptosis for therapeutic use as antiproliferative agents)
 RN 200701-54-8 CAPLUS
 CN Ethanol, 2-[[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 354526-64-0 CAPLUS
 CN Acetic acid, [[1,2,3,4-tetrahydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-6-quinolinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 354526-65-1 CAPLUS
 CN Acetic acid, [[1,2,3,4-tetrahydro-1,2,5,7,8-pentamethyl-2-(4,8,12-trimethyltridecyl)-6-quinolinyl]oxy]-, methyl ester (9CI) (CA INDEX NAME)



IT 261929-53-7P 261929-60-6P 261929-61-7P


261929-62-8P 261929-67-3P 261929-70-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of tocopherols, tocotrienols, other chromans that induce cell apoptosis for therapeutic use as antiproliferative agents)

RN 261929-53-7 CAPLUS

CN Propanoic acid, 3-[[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 261929-60-6 CAPLUS

CN Acetamide, 2-[[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 261929-61-7 CAPLUS

CN Acetic acid, [[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 261929-62-8 CAPLUS

CN Glycine, N-(carboxymethyl)-N-[[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]acetyl]- (9CI)


(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 261929-67-3 CAPLUS

CN 1-Propanamine, 3-[[*(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[*(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl*]oxy]-, hydrochloride (9CI) (CA INDEX NAME)*

Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B



RN 261929-70-8 CAPLUS


CN Ethanol, 2-[[*(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[*(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl*]oxy]-, hydrogen sulfate, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)*

CM 1

CRN 261929-69-5
CMF C31 H54 O6 S

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—CHMe₂



CM 2

CRN 121-44-8
CMF C6 H15 N



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of tocopherols, tocotrienols, other chroman and side chain derivatives for use as antitumor agents and for inducing cell apoptosis
GI



AB Chromans I [R1 = alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxyl, carboxamide, thioamide, saccharide, amine, sulfate, phosphate, etc.; R2, R3, R4 = H, Me, benzylcarboxylate, saccharide, amino, etc.; R5 = alkyl, alkenyl, alkynyl, aryl, heteroaryl, carboxyl, carboxamide; X = O, NH, S] were prepared for pharmaceutical use as antitumor agents and cell apoptosis inducing agents. Thus, tocopherol derivative II (R1 = CH₂CO₂H, X = O) was prepared in 88% yield via O-alkylation of (+)- α -tocopherol with Me bromoacetate. The prepared chromans were tested for cell apoptosis activity against a variety of cancer cell lines.

AN 2000:209907 CAPLUS <>LOGINID::20070718>>

DN 132:237223

TI Preparation of tocopherols, tocotrienols, other chroman and side chain derivatives for use as antitumor agents and for inducing cell apoptosis

IN Kline, Kimberly; Sanders, Bob G.; Hurley, Laurence; Gardner, Robb;
Menchaca, Marla; Yu, Weiping; Ramanan, Puthucode N.; Liu, Shenquan;
Israel, Karen

PA Research Development Foundation, USA

SO PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DT Patent

LA Engl

FAN.CNT 4

PATE

— — — —

PI WO 2000016


W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2345079	A1	20000330	CA 1999-2345079	19990923	<--
AU 9961553	A1	20000410	AU 1999-61553	19990923	<--
AU 757013	B2	20030130			
EP 1115398	A1	20010718	EP 1999-948352	19990923	<--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1325303	A	20011205	CN 1999-812829	19990923	<--
JP 2002526446	T	20020820	JP 2000-573733	19990923	<--
NZ 510732	A	20040130	NZ 1999-510732	19990923	<--
RU 2232758	C2	20040720	RU 2001-111019	19990923	<--
CN 1706838	A	20051214	CN 2005-10003855	19990923	<--

IL 142082 A 20051218 IL 1999-142082 19990923 <--
 TW 592695 B 20040621 TW 1999-88120073 19991117 <--
 ZA 2001002057 A 20020319 ZA 2001-2057 20010313 <--
 PRAI US 1998-101542P P 19980923 <--
 CN 1999-812829 A3 19990923 <--
 WO 1999-US21778 W 19990923 <--
 OS MARPAT 132:237223
 IT 200701-54-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of tocopherols, tocotrienols, other chroman and side chain derivs. for use as antitumor agents and for inducing cell apoptosis)

RN 200701-54-8 CAPLUS
 CN Ethanol, 2-[[2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 261929-53-7P 261929-60-6P 261929-61-7P
 261929-62-8P 261929-67-3P 261929-70-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of tocopherols, tocotrienols, other chroman and side chain derivs. for use as antitumor agents and for inducing cell apoptosis)


RN 261929-53-7 CAPLUS
 CN Propanoic acid, 3-[[2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 261929-60-6 CAPLUS
 CN Acetamide, 2-[[2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 261929-61-7 CAPLUS

CN Acetic acid, [[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 261929-62-8 CAPLUS


CN Glycine, N-(carboxymethyl)-N-[[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 261929-67-3 CAPLUS

CN 1-Propanamine, 3-[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-

trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● HCl

PAGE 1-B

CHMe₂

RN 261929-70-8 CAPLUS

CN Ethanol, 2-[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-, hydrogen sulfate, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 261929-69-5

CMF C31 H54 O6 S


Absolute stereochemistry.

PAGE 1-A



CHMe2

CM 2

CRN 121-44-8
CMF C6 H15 N

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
 AB The present invention provides compns. containing corticosteroid compds. as active agents for the treatment of ailments and diseases of the respiratory tract, particularly the lungs, by way of nasal and pulmonary administration. The corticosteroid compds. are present in a dissolved state in the compns. The compns. can be formulated in a concentrated, essentially non-aqueous form for storage or in a diluted, aqueous-based form for ready delivery. The corticosteroid composition contains an ethoxylated derivative

of vitamin E and/or a polyethylene glycol fatty acid ester as the high-HLB surfactant present in the formulation. The compns. are ideally suited for inhaled delivery with a nebulizer or for nasal delivery. Thus, beclomethasone dipropionate monohydrate (2.8 mg) was dissolved in 997.2 mg of a 2:1 weight/weight mixture of PEG-200 and α -tocopherol polyethylene glycol succinate and the diluted (1:6.65 by volume) with water. The final solution contained 420 μ g beclomethasone dipropionate/mL of solution


AN 2000:14987 CAPLUS <>LOGINID::20070718>>
 DN 132:83652
 TI Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
 IN Saidi, Zahir; Klyashchitsky, Boris
 PA LDS Technologies, Inc., USA
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000000181	A1	20000106	WO 1999-US14351	19990624 <--
	W: AU, CA, IL, JP, MX, NO, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
	PT, SE				
	US 6241969	B1	20010605	US 1998-105838	19980626 <--
	CA 2335900	A1	20000106	CA 1999-2335900	19990624 <--
	AU 9947171	A	20000117	AU 1999-47171	19990624 <--

EP 1089715 A1 20010411 EP 1999-930689 19990624 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 JP 2002519318 T 20020702 JP 2000-556766 19990624 <--
 AT 311174 T 20051215 AT 1999-930689 19990624 <--
 PRAI US 1998-105838 A2 19980626 <--
 WO 1999-US14351 W 19990624 <--
 IT 74707-11-2
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aqueous compns. containing corticosteroids for nasal and pulmonary
 delivery)
 RN 74707-11-2 CAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -[3,4-dihydro-2,5,7,8-tetramethyl-2-
 [(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]- ω -hydroxy-,
 (2R)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— (CH₂)₃—CHMe₂

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
 TI synthesis and activity of polyoxypolypropylenepolyoxyethylene vitamin E
 derivs.
 GI



AB Synthesis and activity of polyoxypolypropylenepolyoxyethylene vitamin E (I) {R = Me; n = 1-3; R1 = (OCH₂CH₂)_m; R2 = [OCH(Me)CH₂]_p} is disclosed. I is prepared by subjecting vitamin E to polyethoxylation and then, to

polypropoxylation to a proper extent. I Is of superior anti-oxidation activity with water solubility. The bent chain of I increases the cross-sectional area of the whole mol., making it difficult for the mol. to penetrate into the skin and safe to apply to the skin. I has superb surface activity by forming close bilayer vesicle structures, like phospholipids or dialkyl surfactants, so it can be advantageously used in the cosmetic, food, and medical industries.

AN 1999:784091 CAPLUS <<LOGINID::20070718>>

DN 132:23111

TI synthesis and activity of polyoxypropylenepolyoxyethylene vitamin E derivs.

IN Kim, Young Dae; Park, Keun Ja; Kim, Jung Soo; Kim, Ji Soo

PA S. Korea

SO PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9962896	A1	19991209	WO 1999-KR270	19990601 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	KR 2000000840	A	20000115	KR 1998-20705	19980603 <--
	AU 9941701	A	19991220	AU 1999-41701	19990601 <--
	EP 1091951	A1	20010418	EP 1999-925424	19990601 <--
	EP 1091951	B1	20020904		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9910916	A	20011016	BR 1999-10916	19990601 <--
	JP 2002517389	T	20020618	JP 2000-552108	19990601 <--
	JP 3547399	B2	20040728		
	AT 223398	T	20020915	AT 1999-925424	19990601 <--
	ES 2183562	T3	20030316	ES 1999-925424	19990601 <--
	CN 1131225	B	20031217	CN 1999-808383	19990601 <--
	US 6355811	B1	20020312	US 2000-701719	20001201 <--
PRAI	KR 1998-20705	A	19980603	<--	
	WO 1999-KR270	W	19990601	<--	
IT	219845-09-7P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(synthesis and activity of polyoxypropylenepolyoxyethylene vitamin E derivs.)

RN 219845-09-7 CAPLUS

CN Poly(oxy-1,2-ethanediyl), α -[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]- ω -hydroxy-, rel- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— (CH₂)₃—CHMe₂

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT